Innoviva IncNASDAQ:INVANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE14.9400
- TODAY'S CHANGE (%)-0.2200 (-1.4512%)
- Bid / Lots14.9300/ 5
- Ask / Lots14.9400/ 9
- Open / Previous Close15.0800 / 15.1600
- Day Range
- 52 Week Range
- Volume292,820
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INVA |
|---|---|---|
| 09:32 ET | 4217 | 15.05 |
| 09:38 ET | 2460 | 15 |
| 09:39 ET | 200 | 14.99 |
| 09:41 ET | 500 | 14.98 |
| 09:43 ET | 700 | 14.97 |
| 09:45 ET | 4084 | 14.98 |
| 09:48 ET | 700 | 14.98 |
| 09:50 ET | 1300 | 14.98 |
| 09:52 ET | 100 | 14.995 |
| 09:54 ET | 500 | 14.98 |
| 09:56 ET | 200 | 14.97 |
| 09:57 ET | 100 | 14.975 |
| 10:01 ET | 200 | 14.97 |
| 10:03 ET | 504 | 14.97 |
| 10:06 ET | 200 | 14.965 |
| 10:08 ET | 100 | 14.9503 |
| 10:12 ET | 956 | 14.9595 |
| 10:14 ET | 1154 | 14.95 |
| 10:19 ET | 445 | 14.96 |
| 10:21 ET | 200 | 14.98 |
| 10:24 ET | 300 | 14.99 |
| 10:26 ET | 200 | 14.99 |
| 10:28 ET | 300 | 14.99 |
| 10:30 ET | 100 | 15 |
| 10:32 ET | 1399 | 15 |
| 10:33 ET | 1300 | 14.99 |
| 10:35 ET | 100 | 14.99 |
| 10:37 ET | 3596 | 14.98 |
| 10:39 ET | 586 | 14.98 |
| 10:42 ET | 200 | 14.97 |
| 10:44 ET | 200 | 14.965 |
| 10:46 ET | 200 | 14.97 |
| 10:50 ET | 600 | 14.98 |
| 10:51 ET | 200 | 14.97 |
| 10:53 ET | 300 | 14.975 |
| 10:55 ET | 100 | 14.98 |
| 11:00 ET | 599 | 14.98 |
| 11:02 ET | 400 | 14.99 |
| 11:04 ET | 400 | 15.02 |
| 11:06 ET | 500 | 15.01 |
| 11:08 ET | 400 | 15.025 |
| 11:09 ET | 507 | 15.02 |
| 11:11 ET | 400 | 15.01 |
| 11:13 ET | 400 | 14.99 |
| 11:15 ET | 300 | 14.98 |
| 11:18 ET | 300 | 14.97 |
| 11:20 ET | 800 | 14.98 |
| 11:22 ET | 600 | 14.99 |
| 11:24 ET | 100 | 14.98 |
| 11:26 ET | 200 | 14.97 |
| 11:27 ET | 200 | 14.97 |
| 11:33 ET | 494 | 14.975 |
| 11:36 ET | 2113 | 14.9975 |
| 11:38 ET | 592 | 14.995 |
| 11:42 ET | 100 | 14.99 |
| 11:45 ET | 200 | 15 |
| 11:47 ET | 200 | 15 |
| 11:49 ET | 1611 | 15.005 |
| 11:51 ET | 300 | 15.005 |
| 11:54 ET | 100 | 15.005 |
| 11:56 ET | 100 | 15.01 |
| 11:58 ET | 796 | 15.005 |
| 12:00 ET | 1219 | 15.03 |
| 12:02 ET | 400 | 15.03 |
| 12:03 ET | 2258 | 14.99 |
| 12:05 ET | 600 | 15.01 |
| 12:07 ET | 1050 | 15.02 |
| 12:09 ET | 200 | 15.025 |
| 12:12 ET | 800 | 15.02 |
| 12:14 ET | 700 | 15.01 |
| 12:16 ET | 100 | 15.01 |
| 12:18 ET | 300 | 15.01 |
| 12:20 ET | 125 | 15.005 |
| 12:21 ET | 300 | 15.01 |
| 12:23 ET | 300 | 15.01 |
| 12:25 ET | 100 | 15.0175 |
| 12:27 ET | 100 | 15.02 |
| 12:30 ET | 100 | 15.015 |
| 12:32 ET | 1243 | 15.01 |
| 12:34 ET | 298 | 15 |
| 12:36 ET | 100 | 15 |
| 12:38 ET | 200 | 15.005 |
| 12:39 ET | 100 | 15.005 |
| 12:45 ET | 500 | 15 |
| 12:48 ET | 100 | 15.01 |
| 12:50 ET | 1356 | 15.025 |
| 12:52 ET | 200 | 15.03 |
| 12:54 ET | 100 | 15.025 |
| 12:56 ET | 300 | 15.025 |
| 12:57 ET | 3601 | 15.03 |
| 12:59 ET | 600 | 15.04 |
| 01:01 ET | 1820 | 15.05 |
| 01:03 ET | 1562 | 15.035 |
| 01:06 ET | 300 | 15.03 |
| 01:08 ET | 300 | 15.02 |
| 01:10 ET | 400 | 15.005 |
| 01:12 ET | 800 | 15 |
| 01:14 ET | 400 | 14.99 |
| 01:15 ET | 572 | 14.99 |
| 01:17 ET | 100 | 14.985 |
| 01:21 ET | 700 | 14.98 |
| 01:24 ET | 300 | 14.975 |
| 01:26 ET | 100 | 14.97 |
| 01:28 ET | 100 | 14.975 |
| 01:30 ET | 408 | 14.98 |
| 01:32 ET | 1000 | 14.985 |
| 01:33 ET | 500 | 15 |
| 01:37 ET | 702 | 14.99 |
| 01:39 ET | 1670 | 15.005 |
| 01:42 ET | 100 | 15.005 |
| 01:44 ET | 200 | 15 |
| 01:46 ET | 100 | 15 |
| 01:48 ET | 542 | 15.01 |
| 01:50 ET | 100 | 15 |
| 01:51 ET | 200 | 15 |
| 01:53 ET | 200 | 15.005 |
| 01:55 ET | 300 | 15.01 |
| 01:57 ET | 2541 | 15.005 |
| 02:00 ET | 300 | 14.995 |
| 02:02 ET | 319 | 14.98 |
| 02:06 ET | 1687 | 14.965 |
| 02:08 ET | 500 | 14.96 |
| 02:09 ET | 848 | 14.95 |
| 02:11 ET | 300 | 14.95 |
| 02:13 ET | 891 | 14.95 |
| 02:18 ET | 200 | 14.96 |
| 02:20 ET | 100 | 14.955 |
| 02:22 ET | 400 | 14.955 |
| 02:24 ET | 300 | 14.956 |
| 02:26 ET | 9608 | 14.97 |
| 02:27 ET | 548 | 14.98 |
| 02:29 ET | 900 | 14.96 |
| 02:31 ET | 400 | 14.965 |
| 02:33 ET | 300 | 14.95 |
| 02:36 ET | 200 | 14.95 |
| 02:38 ET | 100 | 14.955 |
| 02:40 ET | 1000 | 14.96 |
| 02:42 ET | 1289 | 14.96 |
| 02:44 ET | 324 | 14.96 |
| 02:45 ET | 1096 | 14.96 |
| 02:49 ET | 100 | 14.95 |
| 02:54 ET | 2116 | 14.96 |
| 02:56 ET | 900 | 14.95 |
| 02:58 ET | 200 | 14.95 |
| 03:00 ET | 117 | 14.955 |
| 03:02 ET | 3095 | 14.97 |
| 03:05 ET | 914 | 14.98 |
| 03:07 ET | 200 | 14.98 |
| 03:09 ET | 600 | 14.98 |
| 03:12 ET | 100 | 14.98 |
| 03:14 ET | 700 | 14.975 |
| 03:16 ET | 400 | 14.975 |
| 03:18 ET | 7412 | 14.985 |
| 03:20 ET | 4700 | 14.995 |
| 03:21 ET | 2079 | 14.98 |
| 03:23 ET | 400 | 14.97 |
| 03:25 ET | 6684 | 14.95 |
| 03:27 ET | 527 | 14.95 |
| 03:30 ET | 100 | 14.955 |
| 03:32 ET | 24136 | 14.91 |
| 03:34 ET | 1938 | 14.905 |
| 03:36 ET | 4262 | 14.93 |
| 03:38 ET | 4900 | 14.93 |
| 03:39 ET | 10475 | 14.93 |
| 03:41 ET | 3668 | 14.94 |
| 03:43 ET | 1300 | 14.93 |
| 03:45 ET | 3845 | 14.93 |
| 03:48 ET | 5017 | 14.94 |
| 03:50 ET | 3056 | 14.94 |
Yesterday
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Innoviva Inc | 958.5M | 6.7x | -9.89% |
Evolus Inc | 705.8M | -10.5x | --- |
Bavarian Nordic A/S | 1.7B | 7.4x | --- |
Procaps Group SA | 310.3M | 5.2x | --- |
Ligand Pharmaceuticals Inc | 1.3B | 24.0x | -12.71% |
SIGA Technologies Inc | 615.7M | 9.1x | -28.78% |
Company Information
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).
Contact Information
- Headquarters
- 1350 OLD BAYSHORE HIGHWAY, SUITE 400BURLINGAME, CA, United States 94010
- Phone
- 650-238-9600
- Fax
- 302-655-5049
Executives
- Chief Executive Officer
- Pavel Raifeld
- Chief Financial Officer
- Stephen Basso
- Chief Accounting Officer
- Marianne Zhen
- Director
- Odysseas Kostas
- Independent Director
- Mark Dipaolo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $958.5M |
|---|---|
Revenue (TTM) | $310.5M |
Shares Outstanding | 63.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $2.24 |
Book Value | $10.66 |
P/E Ratio | 6.7x |
Price/Sales (TTM) | 3.1 |
Price/Cash Flow (TTM) | 4.4x |
Operating Margin | 36.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
